Back to discover
Disease

Digestive system neuroendocrine tumor, grade 1/2

Also known as GINET, malignant gastrointestinal neuroendocrine tumor, malignant gastrointestinal neuroendocrine tumour, alimentary part of gastrointestinal system neuroendocrine tumor+16 more

GINET, malignant gastrointestinal neuroendocrine tumor, malignant gastrointestinal neuroendocrine tumour, alimentary part of gastrointestinal system neuroendocrine tumor, alimentary part of gastrointestinal system neuroendocrine tumour, digestive system NET, digestive system neuroendocrine tumor, digestive system neuroendocrine tumour, digestive system well differentiated neuroendocrine tumor, digestive system well differentiated neuroendocrine tumour, gastroenteropancreatic NET, gastroenteropancreatic neuroendocrine tumor, gastroenteropancreatic neuroendocrine tumour, gastrointestinal NET, gastrointestinal neuroendocrine tumor, gastrointestinal neuroendocrine tumors, gastrointestinal neuroendocrine tumour, gastrointestinal neuroendocrine tumours, gastrointestinal system neuroendocrine tumor, gastrointestinal system neuroendocrine tumour.

3
Associated genes
3
Related proteins
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Sunitinibapproved

Approval — Gastrointestinal stromal tumour (GIST) Sunitinib Accord is indicated for the treatment of… (2021)

lutetium Lu 177 dotatateapproved

Approval — Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well… (2017)

Everolimusapproved

Approval — Hormone-receptor-positive advanced breast cancer Afinitor is indicated for the treatment… (2009)

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2021emaApproval — Sunitinib· Gastrointestinal stromal tumour (GIST) Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance. Metastatic renal cell carcinoma (MRCC) Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults. Pancreatic neuroendocrine tumours (pNET) Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults. source ↗
2017emaApproval — lutetium Lu 177 dotatate· Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP?NETs) in adults. source ↗
2009emaApproval — Everolimus· Hormone-receptor-positive advanced breast cancer Afinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. Neuroendocrine tumours of pancreatic origin Afinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease. Neuroendocrine tumours of gastrointestinal or lung origin Afinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease. Renal-cell carcinoma Afinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. source ↗
2006emaApproval — Sunitinib· Gastrointestinal stromal tumour (GIST) Sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. Metastatic renal cell carcinoma (MRCC) Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults. Pancreatic neuroendocrine tumours (pNET) Sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. Experience with Sutent as first-line treatment is limited (see section 5.1). source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

3 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

SSTR20.41SSTR50.41SSTR10.40

Disease biology

3 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Somatostatin receptor type 2via SSTR20.41Somatostatin receptor type 5via SSTR50.41Somatostatin receptor type 1via SSTR10.40

Reference

Authoritative identity, definition & identifiers.

Synonyms

GINET, malignant gastrointestinal neuroendocrine tumor, malignant gastrointestinal neuroendocrine tumour, alimentary part of gastrointestinal system neuroendocrine tumor, alimentary part of gastrointestinal system neuroendocrine tumour, digestive system NET, digestive system neuroendocrine tumor, digestive system neuroendocrine tumour, digestive system well differentiated neuroendocrine tumor, digestive system well differentiated neuroendocrine tumour, gastroenteropancreatic NET, gastroenteropancreatic neuroendocrine tumor, gastroenteropancreatic neuroendocrine tumour, gastrointestinal NET, gastrointestinal neuroendocrine tumor, gastrointestinal neuroendocrine tumors, gastrointestinal neuroendocrine tumour, gastrointestinal neuroendocrine tumours, gastrointestinal system neuroendocrine tumor, gastrointestinal system neuroendocrine tumour

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.